-
Midbrain and falx in fetuses with absent corpus callosum at 11-13 weeks.
Lachmann R, Sodre D, Barmpas M, Akolekar R, Nicolaides KH.
Fetal Diagn Ther 2013;33:41-6. -
Asymmetric dimethylarginine, arginine and homoarginine at 11-13 weeks' gestation and preeclampsia: a case-control study.
Khalil AA, Tsikas D, Akolekar R, Jordan J, Nicolaides KH.
J Hum Hypertens 2013;27:38-43. -
Maternal racial origin and adverse pregnancy outcome: a cohort study.
Khalil A, Rezende J, Akolekar R, Syngelaki A, Nicolaides KH.
Ultrasound Obstet Gynecol 2013;41:278-85. -
Proteomic Biomarkers of Preterm Birth Risk in Women with Polycystic Ovary Syndrome (PCOS): A Systematic Review and Biomarker Database Integration.
Galazis N, Docheva N, Nicolaides KH, Atiomo W.
PLoS One 2013;8:e53801. -
Maternal serum visfatin at 11-13 weeks' gestation in preeclampsia.
Ferreira AF, Rezende JC, de Cassia C Oliveira R, Akolekar R, Nicolaides KH.
J Hum Hypertens 2013;27:261-4. -
Hematologic profile of neonates with growth restriction is associated with rate and degree of prenatal Doppler deterioration.
Baschat AA, Kush M, Berg C, Gembruch U, Nicolaides KH, Harman CR, Turan OM.
Ultrasound Obstet Gynecol 2013;41:66-72. -
Fetal fraction in maternal plasma cell-free DNA at 11-13 weeks' gestation: relation to maternal and fetal characteristics.
Ashoor G, Syngelaki A, Poon LC, Rezende JC, Nicolaides KH.
Ultrasound Obstet Gynecol 2013;41:26-32. -
Trisomy 13 detection in the first trimester of pregnancy using a chromosome-selective cell-free DNA analysis method.
Ashoor G, Syngelaki A, Wang E, Struble C, Oliphant A, Song K, Nicolaides KH.
Ultrasound Obstet Gynecol 2013;41:21-5. -
Competing risks model in early screening for preeclampsia by biophysical and biochemical markers.
Akolekar R, Syngelaki A, Poon L, Wright D, Nicolaides KH.
Fetal Diagn Ther 2013;33:8-15. -
Meta-analysis of second-trimester markers for trisomy 21.
Agathokleous M, Chaveeva P, Poon LC, Kosinski P, Nicolaides KH.
Ultrasound Obstet Gynecol 2013;41:247-61. -
Early administration of low-dose aspirin for the prevention of preterm and term preeclampsia: a systematic review and meta-analysis.
Roberge S, Villa P, Nicolaides K, Giguère Y, Vainio M, Bakthi A, Ebrashy A, Bujold E.
Fetal Diagn Ther 2012;31:141-6. pdf -
Metabolomics and first-trimester prediction of early-onset preeclampsia.
Bahado-Singh RO, Akolekar R, Mandal R, Dong E, Xia J, Kruger M, Wishart DS, Nicolaides K.
J Matern Fetal Neonatal Med 2012;25:1840-7. pdf -
Early administration of low-dose aspirin for the prevention of severe and mild preeclampsia: a systematic review and meta-analysis.
Roberge S, Giguère Y, Villa P, Nicolaides KH, Vainio M, Forest JC, von Dadelszen P, Vaiman D, Tapp S, Bujold E.
Am J Perinatol 2012;29:551-6. -
A competing risks model in early screening for preeclampsia.
Wright D, Akolekar R, Syngelaki A, Poon LC, Nicolaides KH.
Fetal Diagn Ther 2012;32:171-8. -
Screening at 11-13+6 weeks' gestation.
Sonek JD, Nicolaides KH, Janku P.
Ceska Gynekol 2012;77:92-104. -
Prefrontal space ratio: comparison between trisomy 21 and euploid fetuses in the second trimester.
Sonek J, Molina F, Hiett AK, Glover M, McKenna D, Nicolaides KH.
Ultrasound Obstet Gynecol 2012;40:293-6. -
Maternal serum insulin-like growth factor-binding protein-3 (IGFBP-3) at 11-13 weeks in preeclampsia.
Sifakis S, Akolekar R, Kappou D, Mantas N, Nicolaides KH.
J Hum Hypertens 2012;26:253-8. -
Maternal serum placental growth hormone at 11-13 weeks' gestation in pregnancies delivering small for gestational age neonates.
Sifakis S, Akolekar R, Kappou D, Mantas N, Nicolaides KH.
J Matern Fetal Neonatal Med 2012;25:1796-9. -
Maternal serum insulin-like growth factor (IGF-I) and binding proteins IGFBP-1 and IGFBP-3 at 11-13 weeks' gestation in pregnancies delivering small for gestational age neonates.
Sifakis S, Akolekar R, Kappou D, Mantas N, Nicolaides KH.
Eur J Obstet Gynecol Reprod Biol 2012;161:30-3. -
First-trimester maternal serum vitamin D and mode of delivery.
Savvidou MD, Makgoba M, Castro PT, Akolekar R, Nicolaides KH.
Br J Nutr 2012;24:1-4.